Atherosclerosis
Volume 176, Issue 1 , Pages 117-123 , September 2004

Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta

  • Nicolas Bousette

      Affiliations

    • Montreal General Hospital, Suite L3-109, 1650 Cedar Avenue, Montreal, Que., Canada H3G 1A4
    • ,
  • Lisa Patel

      Affiliations

    • The Cardiovascular and Urogenital Drug Discovery Group, GlaxoSmithKline, PA, USA
    • ,
  • Stephen A Douglas

      Affiliations

    • The Cardiovascular and Urogenital Drug Discovery Group, GlaxoSmithKline, PA, USA
    • ,
  • Eliot H Ohlstein

      Affiliations

    • The Cardiovascular and Urogenital Drug Discovery Group, GlaxoSmithKline, PA, USA
    • ,
  • Adel Giaid

      Affiliations

    • Montreal General Hospital, Suite L3-109, 1650 Cedar Avenue, Montreal, Que., Canada H3G 1A4
    • Corresponding Author InformationCorresponding author. Tel.: +1 514 934 1934x43841; fax: +1 514 934 8448.

Received 31 January 2003 ,Revised 1 March 2004 ,Accepted 29 March 2004.

References 

  1. Coulouarn Y, Lihrmann I, Jegou S, et al.  Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA. 1998;95(26):15803–15808
  2. Matsushita M, Shichiri M, Imai T, et al.  Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J. Hypertens. 2001;19(12):2185–2190
  3. Ames RS, Sarau HM, Chambers JK, et al.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401(6750):282–286
  4. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J. Pharmacol. 2000;131(3):441–446
  5. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet. 2002;359(9322):1990–1997
  6. Shenouda A, Douglas SA, Ohlstein EH, Giaid A. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J. Histochem. Cytochem. 2002;50(7):885–889
  7. Elshourbagy NA, Douglas SA, Shabon U, et al.  Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J. Pharmacol. 2002;136(1):9–22
  8. Sauzeau V, Le Mellionnec E, Bertoglio J, et al.  Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res. 2001;88(11):1102–1104
  9. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation. 2001;104(1):16–18
  10. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J. Hypertens. 2001;19(12):2191–2196
  11. Sheridan MA, Plisetskaya EM, Bern HA, Gorbman A. Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. Gen. Comp. Endocrinol. 1987;66(3):405–414
  12. Mori M, Sugo T, Abe M, et al.  Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res. Commun. 1999;265(1):123–129
  13. Liu Q, Pong SS, Zeng Z, et al.  Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res. Commun. 1999;266(1):174–178
  14. Giaid A, Yanagisawa M, Langleban D, et al.  Expression of endothelin-1 in lungs of patients with pulmonary hypertension. N. Engl J. Med. 1993;328:1732–1739
  15. Patel L, Charlton SJ, Chambers JK, Macphee CH. Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. Cytokine. 2001;14(1):27–36
  16. Graziani-Bowering GM, Filion LG. Down regulation of CD4 expression following isolation and culture of human monocytes. Clin. Diagn. Lab. Immunol. 2000;7(2):182–191
  17. Gibbs BF, Noll T, Falcone FH, et al.  A three-step procedure for the purification of human basophils from buffy coat blood. Inflamm. Res. 1997;46(4):137–142
  18. Pinderski LJ, Fischbein MP, Subbanagounder G, et al.  Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ. Res. 2002;90(10):1064–1071
  19. Daugherty A, Rateri DL. T lymphocytes in atherosclerosis: the yin-yang of Th1 and th2 influence on lesion formation. Circ. Res. 2002;90(10):1039–1040

PII: S0021-9150(04)00230-8

doi: 10.1016/j.atherosclerosis.2004.03.023

Atherosclerosis
Volume 176, Issue 1 , Pages 117-123 , September 2004

Article Tools

* Image Usage & Resolution